Cargando…
Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy
Concomitant inhibition of MAPK and PI3K signaling pathways has been recognized as a promising strategy for cancer therapy, which effectively overcomes the drug resistance of MAPK signaling pathway-related inhibitors. Herein, we report the scaffold-hopping generation of a series of 1H-pyrazolo[3,4-d]...
Autores principales: | Zhang, Lingzhi, Ju, Qiurong, Sun, Jinjin, Huang, Lei, Wu, Shiqi, Wang, Shuping, Li, Yin, Guan, Zhe, Zhu, Qihua, Xu, Yungen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730961/ https://www.ncbi.nlm.nih.gov/pubmed/33287111 http://dx.doi.org/10.3390/molecules25235693 |
Ejemplares similares
-
Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
por: Huang, Xueqin, et al.
Publicado: (2023) -
Beyond PI3Ks: targeting phosphoinositide kinases in disease
por: Burke, John E., et al.
Publicado: (2022) -
Noncanonical regulation of insulin-mediated ERK activation by phosphoinositide 3-kinase γ
por: Mohan, Maradumane L., et al.
Publicado: (2017) -
Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008) -
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
por: Shuttleworth, S.J, et al.
Publicado: (2011)